Detecting patients with hidden and severe liver disease
Battling a global health challenge that affects millions of people
Liver fibrosis is known as the silent killer. Fat builds, inflammation grows, and fibrosis progresses without symptoms until reaching irreversible stages. In the late stages, the liver has suffered too much damage and starts to shut down. As the liver accounts for more than 500 vital functions, ranging from filtering toxins to regulating metabolism, this becomes fatal. Steatotic liver disease (SLD) is a hidden but globally widespread and severe disease that, however, can be prevented if timely detected.
The numbers speaks for themselves and screams for action
Early detection and diagnosis made easy
LiverPRO is a data-driven and evidence-based Software as a Medical Device (SaMD) that combines data from common blood-based biomarkers to timely and accurately detect liver fibrosis. It is a novel multivariable fibrosis marker that can bridge current gaps in our patient pathways and unlock a preventive healthcare system.
Anchored in science, based on evidence, and driven by data
Trusted and supported throughout the ecosystem
Services and deployment of LiverPRO
Detect undiagnosed liver fibrosis early in clinical practice
Strong diagnostic performance in detecting liver fibrosis, optimised for referral pathway, compatible and scalable within existing patient consultations and touch points, adaptable to local availability of laboratory tests, and CE-certified for broad clinical adoption following high quality criteria.
Accelerate enrolment and increase subject access for clinical trials
Broaden and enrich the screening funnel by leveraging historical Electronic Health Record (EHR) data to proactively find high-risk screening subjects. LiverPRO has demonstrated clinical value on not only expanding screening reach beyond specialist care, but also significantly reducing screen failures.
Uncover true disease burden and treatment effect from historical real-world data
Generate historical real-world data on local level to inform and strengthen HEOR submissions, build real-world liver fibrosis monitoring evidence, or close evidence gap on disease burden. LiverPRO adapts to available data, adding accurate liver insights to existing data sources that otherwise was impossible.
Bringing together expertise and skills to make the changes needed
All to unlock timely treatments that save lives
All to unlock timely treatments that save lives
What is LiverPRO?
LiverPRO is a data-driven and evidence-based Software as a Medical Device (SaMD) that timely and accurately detects liver fibrosis. It combines age with data from minimum three out of nine common blood-based biomarkers to produce an easily interpretable liver fibrosis risk score and category. Typically, patients are grouped into low, moderate, and high risk. In some use cases, the risk score and category are coupled with a clinical recommendation on next steps.
LiverPRO is based on a static machine-learning model that does not continuously learn during use. It is developed and provided by Evido Health to challenge unsustainable patient pathways in clinical practice and trials, unlocking a preventive healthcare system where early diagnosis and interventions with tailored treatments are the norm.
What input variables can be used to run LiverPRO?
LiverPRO is designed for standard and routine laboratory parameters such as liver enzymes and markers of liver functions (i.e. excretion, metabolism, portal hypertension, and synthesis). It combines age with data from minimum three out of nine common blood-based biomarkers, namely, albumin, alkaline phosphatase (ALP), aspartate transaminase (AST), bilirubin, cholesterol, gamma-glutamyl transferase (GGT), international normalised ratio (INR), platelet count, and/or sodium. Due to its inherent flexibility, LiverPRO adapts to whichever three or more biomarkers that are available per individual. The only mandatory input variable is age.
Does the flexibility and number/combination of input variables impact the performance of LiverPRO?
LiverPRO automatically selects the best-performing combination of input variables that is available. The optimal combination depends on the targeted liver fibrosis stage(s). In general, including more input variables can (but does not necessarily) lead to higher performance. If available input variables are predictive of a certain liver fibrosis stage, three variables can yield the same performance as nine input variables.